Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
B-cell Acute Lymphoblastic Leukemia (B-ALL): early-phase trial registry
6 of 7 indexed B-cell Acute Lymphoblastic Leukemia (B-ALL) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 6 currently recruiting · #2,497 of 28,707 conditions by registered trial count
B-cell Acute Lymphoblastic Leukemia (B-ALL): 7 US clinical trials tracked, 6 recruiting.
B-cell Acute Lymphoblastic Leukemia (B-ALL) is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 2 of these trials.
Enrollment posture brief
Registry condition b-cell-acute-lymphoblastic-leukemia-b-all
OPEN 6 | RECR 86% | LATE 0 | EARLY 4 | RANK #2497 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adenovirus (86% recruiting · 7 trials)
B-cell Acute Lymphoblastic Leukemia (B-ALL) lists 6 open slots (86% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for B-cell Acute Lymphoblastic Leukemia (B-ALL) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
B-cell Acute Lymphoblastic Leukemia (B-ALL) is recruiting above its size-band peers.
6 of 7 indexed trials (85.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates B-cell Acute Lymphoblastic Leukemia (B-ALL) research.
AstraZeneca accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most B-cell Acute Lymphoblastic Leukemia (B-ALL) trials plan to enrol fewer than 100 people.
Median target enrolment is 83 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.
-
B-cell Acute Lymphoblastic Leukemia (B-ALL) research is mostly interventional.
5 interventional and 2 observational studies make up this index (71.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
Arkansas Children's Hospital Research Institute
NCT07422337
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
AstraZeneca
NCT06137118
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
Stephan Grupp MD PhD
NCT05480449
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
AstraZeneca
NCT07109219
CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions
St. Jude Children's Research Hospital
NCT07048535
Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
University of Chicago
NCT06785324
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
Novartis Pharmaceuticals
NCT05397496
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on B-cell Acute Lymphoblastic Leukemia (B-ALL) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on B-cell Acute Lymphoblastic Leukemia (B-ALL) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this B-cell Acute Lymphoblastic Leukemia (B-ALL) page
7 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 B-cell Acute Lymphoblastic Leukemia (B-ALL) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most B-cell Acute Lymphoblastic Leukemia (B-ALL) trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This B-cell Acute Lymphoblastic Leukemia (B-ALL) condition card totals 7 registered trials; most-linked intervention PIT565; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.